UK medical devices: a Berkshire breathing-circuit maker out-earns Medtronic's UK arm

No UK entity that actually makes medical devices earns more than Intersurgical, a family-built respiratory-devices manufacturer from Wokingham — the only bigger profit at the top of the table belongs to a sales-and-service arm, not a maker. It made £47.6M of pre-tax profit on £296.9M of turnover — more than Medtronic’s UK arm earned on £690.0M, and a shade more than Johnson & Johnson Medical earned on £654.6M. That inversion is the whole story of the 184 UK medical-device makers that publish a full profit-and-loss, who book £9.0bn of combined turnover: the biggest names in the category are UK sales arms and captive factories of global groups, whose margins are set by intercompany agreement in a head office abroad — while a quieter tier of mid-size British specialists, making bone grafts in Keele and surgical power tools in Hemel Hempstead, earns margins of 20–37% that the giants’ UK accounts never show. The category’s median margin of about 7% describes neither business. Figures are approximate — verify against a company’s own accounts before relying on any single number.

Read the register first

Three things change how you read every number below.

Most of the top of the table is somebody’s UK arm, not a standalone business. Siemens Healthcare, Medtronic, Johnson & Johnson Medical, Becton Dickinson U.K. and Hollister Europe are the British sales-and-service operations of global groups; CooperVision Manufacturing is a set of contact-lens factories running 2,466 staff at a 10% margin to supply its worldwide parent. Whether these entities show a 5% margin, a 10% margin or a loss says more about transfer pricing than about the devices business — none of them belongs in a competitive margin read.

One entity’s profit is four times its turnover. Abbott Diabetes Care, the Witney operation behind Abbott’s glucose-sensing business, shows £691.7M of pre-tax profit on £164.7M of turnover. Profit at four times revenue isn’t a manufacturing margin — it’s intercompany intellectual-property and licensing income (the FreeStyle Libre IP economics landing in the Witney entity’s books). It is excluded from every margin read here, and it’s a useful warning: in a register full of group structures, spectacular numbers are usually structural.

Some groups appear twice. The two CooperVision entities (a manufacturer and a sales company), the two GBUK companies and the two Polarseal entities are pairs of filing layers within single groups, so the £9.0bn headline modestly double-counts, and “two companies growing 41%” in the growth table is one Surrey converter counted twice.

The giants: mostly other people’s margins

…and 173 more. *Abbott’s £691.7M pre-tax profit on £164.7M of turnover is group income flowing through the entity, not a device margin — see above. Convatec’s +35% likely reflects group restructuring as much as trading. Elekta’s £70.0M loss on revenue down 14% and headcount down 5% is the biggest hole in the category — a scale of loss that usually carries impairments or restructuring charges on top of a hard year for capital-equipment orders.

Two rows stand apart. Intersurgical is the counter-example to everything around it: independent of any global medtech group — the founding family controls it through a Liechtenstein family trust — with 873 staff exporting breathing circuits, masks and airway kit worldwide, and earning a 16% margin as reported in its own accounts. That margin is overwhelmingly earned on real sales, though not entirely free of group flows either: a Lithuanian manufacturing sister pays it several million pounds a year in royalties. It is still more absolute profit than UK entities with more than twice its revenue. And Vascutek — trading as Terumo Aortic — shows what a foreign owner running genuine UK manufacturing looks like: 1,008 staff in Renfrewshire making vascular grafts, growing 16% at a 17% margin, the opposite of a thin cost-plus vehicle.

The shape of the market

The distribution has an unusual hole and an unusual tail. The hole: almost nobody sits between £1M and £5M — a device company either stays pre-revenue while it grinds through trials and regulatory approval, or it clears the threshold and scales. The tail: only 17% of the under-£1M companies are profitable, and that’s not failure — it’s the business model. Developing a device means years of loss before the first meaningful sale, and the register’s young cohorts are full of exactly that. Above £5M, this is one of the healthiest manufacturing maps we’ve drawn: roughly four in five companies profitable, all the way up.

The British specialists: where the real margins live

Strip out the group arms and the intercompany constructions, and the companies worth studying are mid-size British specialists — most owning a narrow clinical niche, most exporting, and earning margins the giants’ UK entities never print:

Excluded from this read, deliberately: DePuy International (a 49% margin with 464 staff on £35.0M of turnover is Johnson & Johnson’s internal arithmetic, not an orthopaedics business you can benchmark), Research Instruments (66.7% inside a global fertility group — same problem), and the UK entities of Arjo, Urgo, BD and Beaver-Visitec, whose margins belong to their parents’ stories. The two GBUK entities — £39.4M through 12 employees in one layer, 135 staff in the other — are one Yorkshire single-use group filing in two parts. †Biocomposites files company-only accounts inside a wider group whose consolidated accounts show £141.1M of turnover and £6.2M of pre-tax profit (~4.4%), with sales made principally into the US through a group distribution subsidiary — so its 54.7% entity margin is partly intercompany pricing, the same caveat that excludes DePuy.

The eye-catching number needs the same scepticism the giants got. Biocomposites, the Keele-based maker of synthetic bone-graft and antibiotic-carrier materials, books £37.9M on £69.3M of turnover — 54.7% — but that is a company-only figure inside a private-equity-owned group that sells principally into the US through its own distribution arm; the consolidated group earns roughly a 4% margin on £141.1M, so a large slice of the entity’s margin is intercompany pricing rather than what surgeons pay. The clean standouts are GlucoRx’s 37%, Accora’s 33.5% and De Soutter’s 30.7%: a narrow, clinically-sticky niche where the product is specified by surgeons and the competition is thin. The pattern across the table is consistent — nobody here is a generalist. The money in British medtech is in owning one procedure, one consumable, one operating-theatre habit.

Growth, read with care

Most of this table is not what a growth table usually pretends to be. Accubio’s +166% is a small Scottish diagnostics plant of a Chinese group ramping off a near-zero base while cutting staff and losing £9.1M. Creo Medical and Endomagnetics are the classic medtech development-stage profile — surgical-technology businesses spending heavily ahead of revenue, with growth measured against a base that makes any percentage look dramatic. Rayner, the Worthing intraocular-lens maker, looks like the most interesting loss — but its near-doubled revenue is the very artefact class this report tells you to strip out: the company’s own strategic report attributes the jump to a December 2023 intra-group intellectual-property transfer and a new transfer-pricing structure landing revenue in the UK entity’s books. The genuine signal in that row is the +30% headcount, not the +97%.

The genuine signal is smaller and quieter: Spectrum Medical (+37% revenue, +17% staff, 17.7% margin) and Vitalograph, the Buckingham respiratory-diagnostics maker (+36%, +27% staff, profitable) are growing profitably while hiring — the only combination in this table that reliably means a business winning real orders.

Market structure, ownership and vintage

By manufacturing standards this is a flat market: the top five hold 33.2% of the £9.0bn and the top ten 46.9% — and since those ranks are dominated by the global arms, the independent devices economy is a broad mid-market of £5–100M specialists with no dominant British player at all. That flatness is why the private-equity fingerprint shows: 26 of the 184 companies (14%) carry a Holdings/Group/Bidco-style name, the structural trace of buyouts and planned exits, and the ownership split (109 corporate-owned to 63 individual-owned) leans further corporate every time a founder-run specialist like the ones in the table above gets bought. A map full of 20–50% margin niche leaders under £100M is exactly what a buyout fund’s medtech screen looks like.

The vintage profile connects the two ends of the size chart. The pre-1990 cohort (58 companies) contains the anchors — Intersurgical (1982-founded roots), the ostomy and orthopaedic names. The 33 companies incorporated since 2016 are, overwhelmingly, the under-£1M development-stage tail: device formation is steady, but the decade between incorporation and profitability is the toll every entrant pays.

For adjacent maps, see UK diagnostic imaging, UK pharmaceutical manufacturing and UK biotech.

What the map shows

1. The best independent devices maker out-earns almost every giant’s UK arm. Intersurgical made £47.6M on £296.9M — more pre-tax profit than Medtronic’s £690.0M UK operation, at a margin its own accounts actually mean; only Siemens’ sales-and-service arm books more.
2. The top of the table is intercompany arithmetic. Siemens, Medtronic, J&J, BD and the CooperVision factories book £3bn+ of the category’s revenue at margins set in head office; Abbott’s £691.7M “profit” on £164.7M of turnover is group income, not a device margin.
3. The real margins live in narrow niches. GlucoRx (37%), Accora (33.5%), De Soutter (30.7%) — mid-size specialists that own one procedure or consumable earn margins the generalists never see. (Biocomposites’ 54.7% entity margin is part niche economics, part intercompany pricing inside its group.)
4. Losses are the price of entry, not a distress signal. Only 17% of the under-£1M tier is profitable — the development-stage cohort burning through trials and approval — and the biggest single loss is Elekta’s £70.0M at the top, not the bottom.
5. This is a buyout fund’s map. A flat market of profitable £5–100M niche leaders, 14% already wearing holdco names — expect the corporate-owned share to keep rising.

Methodology and caveats

This covers only the UK medical- and dental-device makers that publish a full profit-and-loss — 184 of a register of around 443, so small workshops, dental laboratories and dormant-adjacent entities filing abridged accounts are invisible here. Margins are not comparable across the category’s different models — a global group’s UK sales arm, a cost-plus captive factory, and an independent maker selling its own products report profit on entirely different bases, and this report only benchmarks the last group against itself. Where a group files through several entities (the CooperVision pair, GBUK, Polarseal), the headline £9.0bn total counts those layers more than once; Abbott Diabetes Care’s pre-tax profit is group income flowing through the entity and is excluded from margin reads; very large one-off losses (Elekta) may include impairments or restructuring rather than ordinary trading; sharp revenue jumps can reflect intra-group IP transfers or transfer-pricing changes rather than trading (Rayner), and company-only entities inside wider groups (Biocomposites) can show margins that are partly intercompany pricing; extreme proportional outliers are excluded from the charts. Each row uses the latest accounts available when the data was assembled, and newer accounts may since have been published. Business descriptions are directional. Figures are approximate — this is analysis, not financial advice; verify any specific figure against the company’s own accounts.